OncoMatch/Clinical Trials/NCT07038096

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Is NCT07038096 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including ZG006 and ZG005 for small cell lung cancer.

Phase 1/2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdNCT07038096Data as of May 2026

Treatment: ZG006 · ZG005 — This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Small Cell Lung Cancer

Neuroendocrine Tumor

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify